Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Diluted Average) (2016 - 2025)

Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 15 years, with the latest figure at $28.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 4.7% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 4.7%, and an annual FY2025 reading of $28.6 million, up 4.7% over the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $28.6 million at Fennec Pharmaceuticals, up from $27.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $31.1 million in Q1 2024, with the low at $26.0 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $27.1 million, with a median of $26.6 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Diluted Average) skyrocketed 30.69% in 2021 and then fell 11.3% in 2025.
  • Tracing FENC's Shares Outstanding (Diluted Average) over 5 years: stood at $26.0 million in 2021, then grew by 1.03% to $26.3 million in 2022, then grew by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then grew by 4.7% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Shares Outstanding (Diluted Average) are $28.6 million (Q4 2025), $27.7 million (Q3 2025), and $27.7 million (Q2 2025).